Boehringer Ingenheim Files Application For Anti-Cancer Drug Afatinib In Europe, Preparing Japan/U.S. Application
This article was originally published in PharmAsia News
Executive Summary
Boehringer Ingenheim announced Sept. 20 it has filed an application to the European Medical Association for EGFR-targeting afatinib for the treatment of non-small cell lung cancer.